Giorgio Trinchieri received his M.D. from the University of Torino, Italy, in 1973. He was a member of the Basel Institute for Immunology (Basel, Switzerland) and an investigator at the Swiss Institute for Experimental Cancer Research (Epalanges sur Lausanne, Switzerland). From 1979 to 1999 he was at Wistar Institute in Philadelphia and became Hilary Koprowski professor and chairman of the Immunology Program. He was then director of the Schering Plough Laboratory for Immunological Research in Dardilly, France, and an NIH Fogarty Scholar at the Laboratory for Parasitic Diseases, NIAID, before becoming director of the Cancer and Inflammation Program (CIP) and chief of the Laboratory of Experimental Immunology at NCI in August 2006.
As CIP director, he oversees the operations of two major intramural laboratories that constitute the major immunologic component of the NCI inflammation and cancer initiative that seeks to partner NCI’s expertise in inflammation and immunology with its cutting-edge cancer etiology and carcinogenesis program. He has been interested in many years in the interplay between inflammation/innate resistance and adaptive immunity and in the role of pro-inflammatory cytokines and interferons in the regulation of hematopoiesis, innate resistance, and immunity. In 1989, his group at the Wistar Institute discovered Interleukin-12 and its role in tumor immunity, infections, and autoimmunity. His main focus of research is now the role of inflammation, innate resistance, and immunity in carcinogenesis, cancer progression, and prevention or destruction of cancer.